Shots:

• The 2nd P-III (PRIME) trial evaluates Dupixent (q2w) with/out topical treatments vs PBO in 151 adults with PN
• The trial met its 1EPs & 2EPs i.e., patients treated with Dupixent showed a reduction in itch and skin lesions (60% vs 18%), patients achieved clear or almost clear skin (48% vs 18%), improvements in measures of overall health-related QoL, skin pain & symptoms of anxiety and depression @24wks. safety results were consistent with that observed in PRIME2. The results will be submitted to regulatory authorities globally in H1’22
• Dupixent is a human mAb that inhibits IL-4 & IL-13 & is approved in the US, EU, Japan & other countries globally for AD, asthma or CRSwNP

Ref: Sanofi | Image: Medcity News